Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF

Aims We examined the effectiveness of a novel cardiopulmonary management wearable sensor (worn for less than 5 mins) at measuring congestion and correlated the device findings with established clinical measures of congestion. Methods and results We enrolled three cohorts of patients: (1) patients with heart failure (HF) receiving intravenous diuretics in hospital; (2) patients established on haemodialysis, and (3) HF patients undergoing right heart catheterization (RHC). The primary outcomes in the respective cohorts were a Spearman correlation between (1) change in weight and change in thoracic impedance (TI) (from enrolment, 24 h after admission to discharge) in patients hospitalized for HF; (2) lung ultrasound B‐lines and volume removed during dialysis with device measured TI, and (3) pulmonary capillary wedge pressure (PCWP) and sub‐acoustic diastolic, third heart sound (S3) in the patients undergoing RHC. A total of 66 patients were enrolled. In HF patients ( n = 25), change in weight was correlated with both change in device TI (Spearman correlation [r sp ] = −0.64, p = 0.002) and change in device S3 (r sp = −0.53, p = 0.014). In the haemodialysis cohort ( n = 21), B‐lines and TI were strongly correlated before (r sp = −0.71, p < 0.001) and after (r sp = −0.77, p < 0.001) dialysis. Volume of fluid removed by dialysis was correlated with change in device TI (r sp = 0.49, p = 0.024). In the RHC cohort ( n = 20), PCWP measured at one time point and device S3 were not significantly correlated (r sp = 0.230, p = 0.204). There were no device‐related adverse events. Conclusions A non‐invasive device was able to detect changes in congestion in patients with HF receiving decongestion therapy and patients having fluid removed at haemodialysis. The cardiopulmonary management device, which measures multiple parameters, is a potentially useful tool to monitor patients with HF to prevent hospitalizations.